Place:
Online
Date:
6-8 October 2022
09:00
SCIENTIFIC PROGRAMME
We invite you to familiarize yourself with the details of the program.
09:00 - 09:05
Opening speech
Jacek Kubica (PL)
09:05 - 09:25
Opening Lecture - Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Diease: Does Less Mean More?
Diana A. Gorog (UK)
09:25 - 09:30
Break
09:30 - 11:30
SESSION 1
09:30 - 09:45
Predictors of in-hospital clinical outcome in COVID-19 patients
Leszek Gromadziński (PL)
09:45 - 10:00
Determinants of anti-SARS-CoV-2 antibodies after vaccination
Magdalena Krintus (PL)
10:00 - 10:15
Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized non-intesive-care COVID-19 pa-tients - SIRIO randomized study
Przemysław Podhajski (PL)
Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized non-intesive-care COVID-19 pa-tients - SIRIO randomized study
10:15 - 10:30
Metformin use in patients hospitalized with COVID-19
Paul A. Gurbel (USA)
10:30 - 10:45
IMPACT of PCSK9 inhibition on clinical outcome in patients with COVID-19 (The IMPACT COVID 19 - SIRIO 5 randomized study)
Eliano P. Navarese (IT)
10:45 - 11:00
Post-COVID-19 rehabilitation
Małgorzata Ostrowska (PL)
11:00 - 11:30
DISCUSSION
11:30 - 11:45
Break
11:45 - 13:45
SESSION 2
11:45 - 12:00
NSTE-ACS ESC Guidelines do not recommend pretreatment with P2Y12 Inhibitor
Piotr Niezgoda (PL)
12:00 - 12:05
NSTE-ACS ESC Guidelines do not recommend pretreatment with P2Y12 Inhibitor. A Contrarian View
Wiktor Kuliczkowski (PL)
12:15 - 12:30
NSTE-ACS ESC Guidelines recommend prasugrel as the preferred P2Y12 Inhibitor
Piotr Adamski (PL)
12:30 - 12:45
NSTE-ACS ESC Guidelines recommend prasugrel as the preferred P2Y12 Inhibitor
Michael Savage (USA)
12:45 - 13:00
Dual antiplatelet therapy in acute coronary syndrome – a comparison of clopidogrel, prasugrel and ticagrelor – a Metaanalysis
Eliano P. Navarese (IT)
13:00 - 13:15
Dual antiplatelet therapy in acute coronary syndrome – a comparison of clopidogrel, prasugrel and ticagrelor – the PL- ACS Registry
Jacek Kubica (PL)
13:15 - 13:45
DISCUSSION
13:45 - 14:00
Break
14:00 - 16:00
SESSION 3
14:00 - 14:15
Use of ultra-thin strut sirolimus-eluting coronary stents in acute coronary syndrome – is it a way to reduce risk of throbosis?
Tommaso Gori (D)
14:15 - 14:30
Microcirculation assessment in patients with acute coronary syndrome undergoing PCI
Jacek Legutko (PL)
14:30 - 14:45
Pharmacodynamics of cangrelor in healthy volunteers
Jolanta Siller-Matula (A)
14:45 - 15:00
Is personalized pharmacotherapeutic approach closed for acute coronary syndrome?
Udaya Tantry (USA)
15:00 - 15:15
Prasugrel or ticagrelor in acute coronary syndrome – is a tailored choice justified? – the PL-ACS registry
Jacek Kubica (PL)
15:15 - 15:30
Diurnal variability of platelet aggregation in patients with myocardial infarction treated with prasugrel and ticagrelor
Piotr Adamski (PL)
15:30 - 16:00
DISCUSSION
16:00 - 16:15
Break
16:15 - 18:00
SESSION 4 - Young Researchers Session: COVID-19 - a Challenge for the Healthcare System
09:00 - 09:20
Lecture of the day
Claudio Borghi (IT)
09:20 - 09:30
Break
09:30 - 11:30
09:30 - 09:45
Impact of COVID-19 pandemic on out-of- hospital cardiac arrest occurence (OSCAR-POL registry)
Jakub Ratajczak (PL)
09:45 - 10:00
Epidemiology, management and survival rate of out-of-hospital cardiac arrest
Klaudiusz Nadolny (PL)
10:00 - 10:15
Imapct of therapeutic hypothermia after a sudden cardiac arrest in patients with myocardial infarction
Agata Sobczyk (PL)
10:15 - 10:30
Effectiveness of ticagrelor in comatose survivors of out-of-hospital cardiac arrest undergoing PCI and therapeutic hypothermia
Marek T. Tomala (PL)
10:30 - 10:45
Effectiveness of ticagrelor in comatose survivors of out-of-hospital cardiac arrest undergoing PCI and therapeutic hypothermia (UNICORN study)
Julia M. Umińska (PL)
10:45 - 11:00
11:00 - 11:30
DISCUSSION
11:30 - 11:45
Break
11:45 - 13:45
SESSION 6
11:45 - 12:00
Recombinant Human Lecithin Cholesterol Acyl transferase in Acute ST-Elevation Myocardial Infarction: Results of REAL-TIMI 63B
Marc Bonaca (USA)
12:00 - 12:15
Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention in patients with prior CABG (The TWILIGHT-CABG study)
Robert Gil (PL)
12:15 - 12:30
Low-dose prasugrel or clopidogrel for elderly patients with acute coronary syndrome? (A sub-study of the ELDERLY ACS 2 trial)
Stefano De Servi (IT)
12:30 - 12:45
Revascularization in STEMI patients with multi-vessel disease (multicenter registry)
Wojciech Wojakowski (PL)
12:45 - 13:00
New insights from an old study - results from the PLATelet inhibition and patients Outcomes (PLATO) trial
Andrzej Budaj (PL)
13:00 - 13:15
PCI versus CABG for treatind in-stent restenosis in unprotected left main (LM-DRAGON registry)
Wojciech Wańha (PL)
13:15 - 13:45
DISCUSSION
13:45 - 14:00
Break
14:00 - 16:05
SESSION 7
14:00 - 14:15
Virtual reality-enhanced rehabilitation in patients with coronary artery disease
Robert Gajda (PL)
14:15 - 14:30
Early standardized clinical judgement for syncope diagnosis in the emergency department
Salvatore di Somma (IT)
14:30 - 14:45
Efficacy and safety of CSK9 inhibitors in patients with familial hypercholesterolemia – an observational study
Krzysztof Chlebus (PL)
14:45 - 15:00
Management and predictors of clinical events in 75 686 patients with acute myocardial infarction
Piotr Jankowski (PL)
15:00 - 15:15
The role of miRNAs in regulation of platelet activity
Marek Postuła (PL)
15:15 - 15:30
Impact of levosimendan on clinical outcome in patients with takotsubo syndrome
Miłosz Jaguszewski (PL)
15:30 - 16:00
DISCUSSION
16:00 - 16:05
Closing remarks
Jacek Kubica (PL)
16:05 - 16:15
Break
16:15 - 18:00
SESSION 8 - ELECTRA-SIRIO 2 trial investigators meeting
09:00 - 13:00
ELECTRA-SIRIO 2 trial investigators meeting
Download
